Taking a job you don't want can still pay off. That's among the several pieces of advice Goldman Sachs CEO David Solomon offered to the company's 2025 class of summer interns, who landed some of the most sought-after and competitive internship positions in finance. "I would tell you that sometimes the best opportunities come from being asked to do something you don't want to do, and actually taking it on and trying to do it. Because that's when people grow the most. That's where I grew the most," Solomon sa ...

>> And Isaac was great. Julie Julie had some issues. >> All right.The fed holding interest rates steady. But the decision comes with some dissent. Our senior economics reporter Steve Liesman joins us right now from Washington Steve good morning.>> Yeah it wasn't Love Island at the fed yesterday. Fed Chair Jay Powell and the federal committee having two dissents there. But they made clear the December rate cut is not a done deal.And I asked Powell whether the fed now has more clarity on the outlook because t ...

Group 1 - A significant short squeeze is occurring in U.S. equity markets, indicated by a surge in speculative buying and options data [1][8] - The five-day moving average of net call volumes for the most shorted stocks reached approximately 4.2 million contracts, marking the second-highest level ever recorded [1][4] - Call volume for heavily shorted U.S. stocks has quadrupled in recent weeks, reflecting a rush by short sellers to cover positions as prices increase [4][5] Group 2 - The current spike in call volume approaches the euphoric highs seen during the 2021 meme stock mania, particularly reminiscent of the GameStop rally [2][5] - The broader market is also experiencing increased call activity, with the five-day moving average of net call volumes for all other stocks doubling to around 10 million contracts, the highest level in four years [4][5] - Retail traders have contributed to sudden rallies in stocks like Krispy Kreme, GoPro, and Opendoor, driven by renewed interest in speculative investments [6] Group 3 - Investor optimism is at a peak, with margin debt on the NYSE reaching an all-time high, surpassing levels seen during the tech bubble [8] - Despite the optimism, there are signs of strain as the latest meme stock rally has quickly fizzled and Bitcoin has retreated from recent highs [8]

#报告 高盛前瞻7月美联储利率决议 https://t.co/FNzCD3DgA5None (@None):None ...

💥BREAKING:SEC APPROVES IN-KIND REDEMPTIONS FOR ALL SPOT ETFs.GIANTS LIKE GOLDMAN SACHS AND JPMORGAN CAN MOVE PHYSICAL BTC IN AND OUT.THIS IS A GAME CHANGER. 🤯 https://t.co/NC1PmkIrnd ...

Business Relationship - JPMorgan is in advanced talks to replace Goldman Sachs in its credit-card joint venture with Apple [1]

Yeah, a lot of names down this morning on earnings, Carl. Yep. And not indeed.Let's get the openings all this morning in the CNBC real time exchange of the big board. It's Evelyn Hill celebrating its 10th listing anniversary retirement solution to the said, Jim, seven or six consecutive record closes in a row and no 1% move in over a month. No, I mean there's no doubt how but what's amazing is is that we have a sea of green even though we just mentioned some serious declines and some of that is David's worl ...

Core Viewpoint - Advanced Micro Devices (AMD) has received a positive endorsement from BofA Securities, maintaining a 'Buy' rating and raising its price target from $175 to $200, indicating a potential increase of about 15% from its last closing price of $173 [1][4]. Group 1: Price Target and Stock Performance - The new price target of $200 represents a 15% increase from AMD's last closing price of $173 [1]. - AMD's stock has rallied 11% over the past week and ended the previous session up over 4% [1]. Group 2: Earnings Expectations and Revenue Projections - BofA expects AMD to exceed consensus in both Q2 and Q3 earnings, forecasting revenues of $7.5 billion and $8.5 billion, respectively [7]. - For the full year 2025, BofA projects AMD's revenue to reach $33 billion and earnings per share of $4.10, both surpassing current Wall Street estimates [7]. Group 3: Market Opportunities and Drivers - Potential resumption of AI chip shipments to China in the second half of the year could contribute up to $1 billion in sales in 2025 and as much as $2 billion by 2026 [4]. - AMD is benefiting from stronger-than-expected pricing for its MI355X chips, with units selling for over $20,000, exceeding the consensus estimate of $17,000 [5]. - Strong demand for cloud-related GPUs, improving year-over-year comparisons in the PC segment, and steady enterprise interest from companies like Hewlett Packard Enterprise and Texas Instruments are also positive drivers [5]. Group 4: Market Share Projections - AMD is projected to capture more than 30% of the global CPU market by 2026, up from just under 20% in 2023 [8]. - Its share of the competitive AI GPU space could grow to 4% to 5%, supported by strategic shifts and manufacturing uncertainties at Intel [8]. Group 5: Analyst Ratings - Wall Street remains bullish on AMD stock, with Goldman Sachs reiterating a 'Buy' rating with a $140 target, while HSBC upgraded AMD to 'Buy' with a $200 target [8][9]. - Citi maintained a 'Hold' but raised its target from $120 to $145, indicating improved expectations [9].

Group 1 - Morgan Stanley projects the S&P 500 to reach 7,200 by mid-2026, indicating a 12% increase from the last close of 6,389 [1] - The bullish outlook is supported by favorable economic factors, including a "rolling recovery" environment, improved operating leverage, AI adoption, a weakening U.S. dollar, and tax savings from the Inflation Reduction Act [2][4] - Anticipated interest rate cuts by the Federal Reserve in early 2026 and easing year-over-year growth comparisons further bolster the positive outlook [3] Group 2 - Oppenheimer raised its year-end S&P 500 target to 7,100 from 5,950, citing robust corporate earnings and favorable macroeconomic conditions [5] - Other institutions have also revised their forecasts upward, including BMO (6,700), Goldman Sachs (6,600), and Bank of America (6,300) [5] - Despite the bullish sentiment from many firms, Evercore ISI and HSBC remain cautious with the lowest targets at 5,600 [7]

Core Viewpoint - Iovance Biotherapeutics' stock has seen a significant decline, down approximately 75% from its peak in December, leading to mixed opinions among analysts regarding its valuation and future potential [1][2][3]. Group 1: Analyst Ratings and Price Targets - Chardan Capital maintains a buy rating with a price target of $25, suggesting a potential gain of about 720% from the current price of $3.05 [2]. - The consensus price target for Iovance is $10 per share, indicating a potential average gain of 228% [3]. Group 2: Product Approval and Market Potential - The FDA approved Iovance's first product, Amtagvi, in February 2024, which is a cell-based treatment for advanced melanoma [5]. - In clinical trials, Amtagvi demonstrated a tumor shrinkage response in 31.5% of patients who had previously failed PD-1 blocking therapies [6]. - Among 41 patients evaluated post-approval, 20 showed smaller tumors or no tumors, with a response rate of 60.9% in those with limited prior treatments [7]. Group 3: Challenges Facing Iovance - Goldman Sachs downgraded Iovance to sell, citing concerns over a slower-than-expected launch of Amtagvi [8]. - The launch faces challenges including the FDA's approval based on tumor shrinkage rather than overall survival benefits, a small sales team, and the complex administration of the treatment [9][10]. - Sales for Amtagvi reached $43.6 million in Q1 2025, which is below expectations for a blockbuster product [11]. Group 4: Financial Outlook and Market Valuation - Iovance's market cap is approximately $1.05 billion, which is considered low for a biotech company with a new product [12]. - Management projects sales between $250 million and $300 million for the year, with biotech stocks typically trading at mid-to-high single-digit multiples of trailing sales [12]. - The resignation of the CFO raises concerns about future sales guidance, as such changes are often associated with disappointing forecasts [14].